ADHD | CARLAT PUBLISHING

Expert Q&A

ADHD: Beyond Stimulants

January 1, 2025

Nicholas J. Nissen, MD

Concierge psychiatrist, specializing in nonstimulant management of ADHD and anxiety disorders. Austin, TX.

Dr. Nissen has no financial relationships with companies related to this material.

Stimulants may hold the prize for effect size in ADHD, but nonstimulants have advantages for the right patient. Nicholas Nissen shows us how to use five medications, two supplements, and lifestyle approaches in ADHD.

When Bipolar and ADHD Overlap: Treatment 2

December 2, 2024

Kellie Newsome, PMHNP and Chris Aiken, MD

How to treat ADHD in bipolar disorder without destabilizing mood part 1: stimulants and non-stimulants.

When Bipolar and ADHD Overlap: Treatment 1

November 25, 2024

Kellie Newsome, PMHNP and Chris Aiken, MD

How to treat ADHD in bipolar disorder without destabilizing mood part 1: stimulants and non-stimulants.

When Bipolar and ADHD Overlap: Diagnosis

November 18, 2024

Kellie Newsome, PMHNP and Chris Aiken, MD

You’ll never be 100% sure if a patient has bipolar, ADHD, or both, but we’ll get you as close as we can.

Research Update

Overdiagnosis of ADHD

November 1, 2024

Alvin Marquez, MD

Alvin Marquez, MD. Dr. Marquez has no financial relationships with companies related to this material.

A recent study reveals the limitations of ADHD screening tools, highlighting the risks of overdiagnosis in adults based on self-reports.

News of Note

Azstarys: Vyvanse’s Dexmethylphenidate Cousin

November 1, 2024

Chris Aiken, MD

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report.

Dr. Aiken has no financial relationships with companies related to this material.

Azstarys is methylphenidate's answer to Vyvanse. But how does its abuse potential compare?

Clinical Update

Vyvanse Goes Generic: An Amphetamine Apart

November 1, 2024

David Liebers, MD and Chris Aiken, MD

David Liebers, MD. Psychiatry resident at NYU Langone, Department of Psychiatry.

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Dr. Liebers and Dr. Aiken have no financial relationships with companies related to this material.

Known for lower misuse potential and a smoother effect profile, lisdexamfetamine stands out in ADHD treatment. This article explores what makes it unique among stimulants.

Top 10 Findings: Alcohol, ADHD, and Antipsychotics

October 28, 2024

Chris Aiken, MD and Kellie Newsome, PMHNP

A new med combo for alcohol use disorder, antipsychotic dose reduction in schizophrenia, and two new tips for using stimulants in ADHD.

Research Update

How Safe Is Methylphenidate?

October 1, 2024

Earth Hasassri, MD

Earth Hasassri, MD. Dr. Hasassri has no financial relationships with companies related to this material.

Most of us use methylphenidate (MPH) routinely in patients across a wide range of ages and even diagnoses. But what are the long-term side effects of MPH? This research update gives you a current understanding of the potential risks with helpful guidance on how to proceed with care.

Research Update

Stimulants in Preschool-Age Children

October 1, 2024

Earth Hasassri, MD

Earth Hasassri, MD. Dr. Hasassri has no financial relationships with companies related to this material.

We are understandably hesitant to treat young children with medication for ADHD. Does it work? Will there be worse or different side effects? This research update will help you weigh the risks and benefits of pursuing stimulant treatment for ADHD in our smallest patients.